Charles River Laboratories International, Inc. (NYSE:CRL) Position Cut by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 30.3% in the 4th quarter, Holdings Channel reports. The fund owned 209 shares of the medical research company’s stock after selling 91 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Charles River Laboratories International were worth $39,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Virtu Financial LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth about $601,000. JPMorgan Chase & Co. grew its holdings in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares in the last quarter. State Street Corp increased its position in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC raised its stake in Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in Charles River Laboratories International during the 3rd quarter worth $966,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE CRL opened at $153.20 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The stock’s 50-day moving average price is $177.23 and its two-hundred day moving average price is $191.71. The company has a market cap of $7.83 billion, a PE ratio of 19.17, a PEG ratio of 6.47 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Wall Street Analyst Weigh In

CRL has been the topic of a number of research analyst reports. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. UBS Group restated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Finally, CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).